Study guide
7.3 Regional & Localized Therapy Administration
Advanced Oncology Certified Nurse Practitioner AOCNP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide
2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening
2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling
3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging
3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment
4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship
4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence
5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy
5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring
6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies
6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology
7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy
7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies
8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response
8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)
9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety
9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions
10 Chapter 10: Supportive Care - Symptom & Comorbidity Management
10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management
11 Chapter 11: Oncologic Emergencies
11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH
12 Chapter 12: Psychosocial Issues
12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources
13 Chapter 13: Professional Practice & Roles of the APRN
13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education
7.3 Regional & Localized Therapy Administration
Key Takeaways Explain This Topic AI
Regional delivery exploits first-pass extraction to raise local drug concentration many-fold while limiting systemic exposure, and is only rational when disease is confined to that compartment.
Only a defined set of agents may be given intrathecally — methotrexate, cytarabine including liposomal formulations, hydrocortisone, and thiotepa; vinca alkaloids given intrathecally cause fatal ascending myeloencephalopathy.
Intraperitoneal cisplatin and paclitaxel improve survival in optimally debulked advanced ovarian cancer but cause substantially more catheter complications, abdominal pain, and nephrotoxicity than intravenous therapy.
Hepatic arterial infusion of floxuridine exploits the hepatic artery's supply of liver metastases, with biliary sclerosis as the characteristic dose-limiting toxicity.
Post-embolization syndrome, consisting of fever, right upper quadrant pain, nausea, and transaminase elevation, occurs in most patients after chemoembolization and is managed supportively rather than as infection.
Last updated: August 2026
7.3 Regional & Localized Therapy Administration
Blueprint focus: ONCC Domain II.C — Localized therapy (for example intravascular, intraperitoneal, intrathecal, intra-arterial). Regional therapy is tested heavily on safety rules and route-specific complications , not on efficacy data.
The Pharmacologic Rationale
Regional delivery is justified by two related principles.
Compartmental advantage. Delivering a drug directly into a space that systemic circulation penetrates poorly — the cerebrospinal fluid, the peritoneal cavity, the bladder — can raise local concentration by one to three orders of magnitude.
First-pass extraction. An organ that extracts most of a drug on first pass (the liver with floxuridine, for example) receives a very high local dose while systemic exposure stays low.
Regional therapy is only rational when disease is genuinely confined to that compartment. It does not treat systemic disease, and adding it to an inappropriate patient produces toxicity without benefit.
Intrathecal Chemotherapy
Intrathecal therapy treats or prevents leptomeningeal disease, most often in acute lymphoblastic leukemia, aggressive lymphomas, and leptomeningeal metastases from breast and lung cancer.
Routes: lumbar puncture, or an Ommaya reservoir — a subcutaneous scalp reservoir connected to a ventricular catheter that provides repeated access and better drug distribution throughout the CSF.
Agents that may be given intrathecally:
Agent Typical use Notes
Methotrexate CNS prophylaxis and treatment Chemical arachnoiditis is the commonest acute reaction; leucovorin rescue is given systemically, never intrathecally
Cytarabine CNS leukemia and lymphoma Liposomal cytarabine gives sustained levels and requires concurrent dexamethasone to prevent chemical arachnoiditis
- Hydrocortisone Added to reduce arachnoiditis Part of the classic triple intrathecal regimen
- Thiotepa Alternative agent Crosses the blood-brain barrier well
- The single most important safety rule in oncology nursing
Vinca alkaloids are fatal if given intrathecally. Intrathecal vincristine causes a progressive ascending myeloencephalopathy that is essentially uniformly fatal. Standard safeguards:
Vincristine must be dispensed only in a small-volume intravenous minibag , never in a syringe.
The bag carries the label "For intravenous use only — fatal if given by other routes."
Vinca alkaloids and intrathecal agents must never be transported, stored, or present in the treatment area at the same time ; intrathecal doses are handled in a separate time and place.
Independent double verification of drug, dose, and route immediately before administration.
Post-procedure nursing care: monitor for headache, nausea, fever, meningismus, and neurologic change; position per institutional protocol; observe the puncture site for CSF leak; and know that a post-dural-puncture headache is positional and may require a blood patch.
Intraperitoneal Therapy
Indication: optimally debulked (residual disease under 1 cm) advanced epithelial ovarian cancer, and selected peritoneal surface malignancies.
Standard agents: cisplatin and paclitaxel, delivered through an implanted intraperitoneal port and catheter, typically with 1 to 2 liters of warmed fluid.
Toxicity profile: intraperitoneal therapy produces substantially more abdominal pain and distention, nausea, catheter infection, catheter obstruction and leakage, bowel injury, nephrotoxicity, and neuropathy than intravenous therapy. Completion rates are correspondingly lower, and the decision requires an explicit conversation about the survival benefit weighed against the burden.
Nursing management: verify catheter patency and absence of infection before each instillation; warm the infusate to body temperature; instill by gravity; reposition the patient side to side to distribute drug across peritoneal surfaces; monitor abdominal girth, pain, and respiratory effort; aggressive hydration and electrolyte replacement with cisplatin.
HIPEC (hyperthermic intraperitoneal chemotherapy) delivers heated chemotherapy intraoperatively immediately after cytoreductive surgery — most often for appendiceal and colorectal peritoneal metastases and pseudomyxoma peritonei. Postoperative care focuses on fluid shifts, hypothermia or hyperthermia, electrolyte derangement, prolonged ileus, and neutropenia.
Intra-Arterial and Intravascular Therapy
Hepatic arterial infusion (HAI). An implanted pump delivers floxuridine into the hepatic artery. Liver metastases derive their blood supply almost entirely from the hepatic artery while normal hepatocytes are supplied mainly by the portal vein, so tumor is exposed selectively. Floxuridine is nearly completely extracted on first pass, which keeps systemic toxicity low. The characteristic dose-limiting toxicity is biliary sclerosis — a rising alkaline phosphatase and bilirubin that mandates dose reduction or discontinuation. Dexamethasone is often added to the pump to mitigate it. Nursing care centers on pump refill scheduling, site assessment, and monitoring liver enzymes at every refill.
Transarterial chemoembolization (TACE) delivers chemotherapy plus embolic particles into the tumor-feeding artery, most often for hepatocellular carcinoma. Transarterial radioembolization (TARE, Y-90) delivers yttrium-90 microspheres instead.
Post-embolization syndrome occurs in most patients within 24 to 72 hours: fever, right upper quadrant pain, nausea, fatigue, and transaminase elevation . It is a predictable inflammatory response to tumor necrosis, not infection, and is managed with analgesia, antiemetics, antipyretics, and hydration. Distinguish it from hepatic abscess or cholecystitis when fever is prolonged or rigors appear.
Isolated limb perfusion or infusion delivers high-dose melphalan to an extremity isolated from systemic circulation for in-transit melanoma or extremity sarcoma; compartment syndrome and regional toxicity are the concerns.
Intravesical and Intrapleural Therapy
Intravesical therapy for non-muscle-invasive bladder cancer uses BCG (an immunotherapy) or intravesical chemotherapy such as mitomycin or gemcitabine, instilled through a urinary catheter and retained for about 2 hours with periodic repositioning.
BCG is a live attenuated organism . It is contraindicated with gross hematuria, traumatic catheterization, active urinary tract infection, or significant immunosuppression, because of the risk of disseminated BCG infection presenting as persistent high fever and systemic illness — an emergency requiring antituberculous therapy.
Teach patients to sit to void for 6 hours after instillation and to disinfect the toilet with bleach.
Expect transient dysuria, frequency, and hematuria; escalate for fever above 38.5 °C persisting beyond 24 to 48 hours.
Intrapleural therapy is primarily pleurodesis with talc or doxycycline through a chest tube or at thoracoscopy for recurrent malignant pleural effusion, or drainage through an indwelling tunneled pleural catheter. Pain and fever are expected; monitor for re-expansion pulmonary edema after large-volume drainage, and drain no more than about 1.5 liters at one sitting or until chest discomfort or cough develops.